Swedish Orphan Biovitrum (Sobi) has acquired US-based biotech company Arthrosi Therapeutics for Skr9.1bn ($950m) in cash, with additional payments up to Skr5.3bn ($550m) based on milestones. The deal provides access to pozdeutinurad, a URAT1 inhibitor for gout, currently in Phase III trials with results expected in 2026.

Arthrosi is developing pozdeutinurad to lower serum urate levels, reduce gout flares, and address tophi in patients with progressive gout. Completion of the transaction is expected in the first half of 2026, pending customary closing conditions. Sobi aims to finance the deal through debt and expects positive growth and margin impact.

The acquisition is seen as a move to expand Sobi’s gout treatment pipeline, with potential transformative benefits for individuals with gout. Sobi plans to utilize debt and credit facilities for the upfront payment, with Barclays Bank as financial advisor and McDermott, Will & Schulte as legal advisor for the transaction.

Read more at Yahoo Finance: Sobi buys Arthrosi to expand gout treatment pipeline